Unanswered questions regarding the use of PARP inhibitors for patients with mCRPC

Alan Haruo Bryce, MD, Mayo Clinic, Rochester, MN, talks on key challenges regarding the use of PARP inhibitors for patients with metastatic castration-resistant prostate cancer (mCRPC), including with optimizing with patient selection and optimizing the timing and the optimal combinations. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.